Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 7/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | HPGDS | O60760 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30718161 | 1.00 | GPR119 (0.44) | GPR119MTORPIK3CAAGTR2RET | |
| SCHEMBL29931593 | 0.86 | AGTR2 (0.47) | MTORPIK3CAAGTR2HDAC8 | |
| SCHEMBL27029442 | 0.83 | ACHE (0.55) | GPR119PIK3CAPDE10A | |
| SCHEMBL30718211 | 0.83 | ACHE (0.55) | GPR119PIK3CAPDE10A | |
| SCHEMBL31254485 | 0.81 | GPR119 (0.46) | GPR119MTORRETUSP30PDE10A | |
| SCHEMBL29115840 | 0.78 | MAPKAPK2 (0.41) | MTORPIK3CAHDAC8 | |
| SCHEMBL30718176 | 0.78 | MAPKAPK2 (0.41) | MTORPIK3CAHDAC8 | |
| SCHEMBL30718218 | 0.78 | MAPKAPK2 (0.41) | MTORPIK3CAHDAC8 | |
| SCHEMBL27063742 | 0.76 | PIK3CA (0.43) | MTORPIK3CAAGTR2HDAC8 | |
| SCHEMBL16933645 | 0.76 | GPR119 (0.47) | GPR119AGTR2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199654-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | SUZHOU GUOKUANG PHARMTECH. CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| EP-4310081-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | Suzhou Guokuang Pharmtech. Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| EP-4310081-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | Suzhou Guokuang Pharmtech. Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-117157284-A | CTLA-4 small molecule degradation agent and application thereof | 苏州国匡医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199654-A1 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | CD274, PDCD1, PDCD1LG2 | GPR119 1088/4885MTOR 509/4885PIK3CA 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.